Private equity investment in physician practices has surged in recent years, reshaping the landscape of healthcare delivery across the United States. As private equity firms seek to consolidate fragmented medical markets and drive profitability, physicians and healthcare organizations face both promising opportunities and significant legal and operational risks. Understanding the implications of private equity ownership…
Guiding your family through the upheaval and high emotions of a stressful personal episode requires diplomacy and a deft touch. If your health is failing and your family members are left to handle things themselves, you can still provide a reassuring presence—by planning with advance care directives and other estate tools. Getting everyone in the…
On April 23, 2024, the Federal Trade Commission issued a final rule federally banning covenants not to compete for almost all workers. The final rule prohibits employers from requiring covenants not to compete for their workers and also voids all existing covenants not to compete, with very limited exceptions. The final rule defines “worker” very…
On March 7, 2024, an LSD formula (MM120) was granted Breakthrough Therapy Status by the FDA. According to the FDA, the “Breakthrough Therapy Status” designation requires preliminary clinical evidence that demonstrates the drug may have substantial improvement on at least one clinically significant endpoint over available therapy. This also means the LSD formula has received…
President Biden has signed the 2024 National Defense Authorization Act into law, and it’s a big win for our service members! The NDDA mandates the Department of Defense to develop a process for service members with PTSD or TBIs to participate in clinical trials using psilocybin, MDMA, ibogaine, and 5-MeO-DMT. This is a significant step…
Daniels, Porco & Lusardi, LLP is pleased to welcome Robert (Bob) J. Baror as a partner of the firm. Bob is admitted to practice in New York, Connecticut, Maryland, and Washington, D.C. An accomplished litigator and employment lawyer, Bob regularly represents employees who have suffered workplace injustices and has served as counsel to Fortune 500…
Attention mental healthcare providers! Exciting news in the world of mental health therapy. On December 12, 2023, MAPS Public Benefit Corporation filed the first New Drug Application for any psychedelic-assisted therapy. If approved, MDMA-assisted therapy would be the first psychedelic-assisted therapy approved for PTSD. This would require the DEA to reschedule MDMA, making it available…
The only psychedelic substance which can be prescribed by New York providers at this time is ketamine (for off-label use) and Spravato (which only includes the esketamine molecule). While Spravato has been approved by the FDA for treatment of depression, ketamine is not currently FDA approved for such treatment. New York providers are prescribing compounded ketamine to…
This is an exciting time for mental health professionals (and for health law attorneys) in New York! Following on the heels of Colorado and Oregon, New York currently has a number of bills pending which would legalize psychedelics for therapeutic use and also legalize the personal use of certain natural plant or fungus-based hallucinogens. These…
Mobile diagnostic units provide benefits for both referring physicians and their patients. They allow referring physicians to provide diagnostic services to their patients in the convenience of their own office, thereby saving their patients the trouble of traveling to another location for diagnostic tests. A common arrangement with respect to mobile diagnostic units is the following: The reading physician…